Another ADC Buyout - Just not SPL, page-14

……. and yet another ADC buyout …. again - just not Starpharma …. Even if Starpharma did a small deal like this is would be circa $2 per share …. perhaps our ADCs just don’t stack up ? Would make sense I suppose given one of our ADC research agreement partners Merck committed up to $22 billion with Daiichi less than 2 months ago


Bristol Myers Squibb claims to be taking on Merck in the ADC space and yet that still hasn’t enticed Merck to secure our ADCs after 2+ years of looking under the hood / performing preclinical ADC studies ?


https://www.fiercebiotech.com/biote...Pharma Tracker&oly_enc_id=9563F4064234D3D


BMS pays $800M upfront for antibody-drug conjugate, opening new front in Merck rivalry


Bristol Myers Squibb has filled the antibody-drug conjugate (ADC) shaped hole in its pipeline by following the increasingly well-trodden path to China, handing SystImmune $800 million upfront for a phase 2 solid tumor candidate as part of a deal worth up to $8.4 billion.


Until now, BMS has been notably absent from the ADC dealmaking frenzy, staying on the sidelines while rivals for the cancer drug market such as AstraZeneca, Gilead and Merck & Co. hoovered up assets. BMS outlined work on ADC degraders at its R&D day in September, explaining how using an antibody to direct a CELMoD to its target could improve efficacy and tolerability but has mostly stayed out of the main fray.


That changed after the market closed Monday when the Big Pharma unveiled a deal for the ex-China rights to the EGFRxHER3 bispecific BL-B01D1. BMS is betting big on the candidate, paying $800 million upfront and committing up to $500 million in near-term milestones to land the asset.